1. Home
  2. BRNS vs RFL Comparison

BRNS vs RFL Comparison

Compare BRNS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barinthus Biotherapeutics plc

BRNS

Barinthus Biotherapeutics plc

N/A

Current Price

$0.73

Market Cap

55.9M

Sector

Health Care

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.31

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRNS
RFL
Founded
2016
2017
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
55.9M
54.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BRNS
RFL
Price
$0.73
$1.31
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
84.8K
206.4K
Earning Date
11-07-2025
12-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,029,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1766.46
47.63
52 Week Low
$0.64
$1.12
52 Week High
$2.92
$3.19

Technical Indicators

Market Signals
Indicator
BRNS
RFL
Relative Strength Index (RSI) 45.06 54.94
Support Level $0.70 $1.12
Resistance Level $0.74 $1.28
Average True Range (ATR) 0.05 0.09
MACD 0.01 0.01
Stochastic Oscillator 50.13 78.26

Price Performance

Historical Comparison
BRNS
RFL

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: